{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-040241","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.794076+00:00","generated_at":"2026-05-24T16:00:48.807836+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sana reports Q4 net loss $49.1M; positive T1D islet cell data at 12 weeks","bullets":["HIP-modified islet cells (UP421) produced C-peptide and MMTT response at 12 weeks without immunosuppression; no safety issues.","Cash $152.5M at Dec 31, 2024; cash runway expected into 2026.","Net loss $49.1M in Q4 2024 vs $88.1M in Q4 2023; full year 2024 net loss $266.8M.","Enrolling GLEAM (SC291 autoimmune) and VIVID (SC262 B-cell cancers); data expected in 2025.","Appointed Dhaval Patel as CSO and Tricia Stewart as CPO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-040241","json":"https://secwatch.observer/filing/0000950170-25-040241.json","markdown":"https://secwatch.observer/filing/0000950170-25-040241.md","text":"https://secwatch.observer/filing/0000950170-25-040241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000095017025040241/0000950170-25-040241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000095017025040241/sana-20250317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T16:00:48.807836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}